Lvi Vec News Today

Immuno-oncology company Genelux Corp. (GNLX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development program of Olvi-Vec (olvimulogene nanivacirepvec) for the treatment of patients with platinum resistant/refractory ovarian cancer.

- Expanded executive team as Lourie Zak appointed Chief Financial Officer -  - Extended clinical focus on systemic administration in small cell lung...